TW202406554A - 治療神經發炎性病況之方法 - Google Patents

治療神經發炎性病況之方法 Download PDF

Info

Publication number
TW202406554A
TW202406554A TW112116504A TW112116504A TW202406554A TW 202406554 A TW202406554 A TW 202406554A TW 112116504 A TW112116504 A TW 112116504A TW 112116504 A TW112116504 A TW 112116504A TW 202406554 A TW202406554 A TW 202406554A
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
group
mmol
disease
Prior art date
Application number
TW112116504A
Other languages
English (en)
Chinese (zh)
Inventor
凱文 雀曲
羅伯特 泰勒
傑韋爾 強斯頓
漢司 Ｊ 莫比司
道格拉斯 保特曼
蓮恩 Ｈ 卡娃斯
Original Assignee
美商雅斯娜製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商雅斯娜製藥公司 filed Critical 美商雅斯娜製藥公司
Publication of TW202406554A publication Critical patent/TW202406554A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112116504A 2022-05-04 2023-05-03 治療神經發炎性病況之方法 TW202406554A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263338328P 2022-05-04 2022-05-04
US63/338,328 2022-05-04
US202263414111P 2022-10-07 2022-10-07
US63/414,111 2022-10-07
US202263424352P 2022-11-10 2022-11-10
US63/424,352 2022-11-10
US202363447432P 2023-02-22 2023-02-22
US63/447,432 2023-02-22

Publications (1)

Publication Number Publication Date
TW202406554A true TW202406554A (zh) 2024-02-16

Family

ID=86693083

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112116504A TW202406554A (zh) 2022-05-04 2023-05-03 治療神經發炎性病況之方法

Country Status (10)

Country Link
US (1) US20250275976A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515045A (cg-RX-API-DMAC7.html)
KR (1) KR20250005230A (cg-RX-API-DMAC7.html)
CN (1) CN119156217A (cg-RX-API-DMAC7.html)
AU (1) AU2023263997A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248640A1 (cg-RX-API-DMAC7.html)
IL (1) IL316281A (cg-RX-API-DMAC7.html)
TW (1) TW202406554A (cg-RX-API-DMAC7.html)
WO (1) WO2023215377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538382A (ja) * 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20140094413A1 (en) 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2021371026A1 (en) * 2020-11-02 2023-06-15 LeonaBio, Inc. Bicyclic compounds and uses thereof for the treatment of diseases
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases

Also Published As

Publication number Publication date
CA3248640A1 (en) 2023-11-09
AU2023263997A1 (en) 2024-10-24
IL316281A (en) 2024-12-01
US20250275976A1 (en) 2025-09-04
CN119156217A (zh) 2024-12-17
WO2023215377A1 (en) 2023-11-09
EP4518865A1 (en) 2025-03-12
KR20250005230A (ko) 2025-01-09
JP2025515045A (ja) 2025-05-13

Similar Documents

Publication Publication Date Title
TWI918751B (zh) 用於治療疾病之雙環化合物及其用途
US12209096B2 (en) Compounds and compositions for inducing chondrogenesis
AU2023263997A1 (en) Methods of treating neuroinflammatory conditions
TW202408503A (zh) 治療纖維化之方法
TW202339756A (zh) 雙環化合物用於治療疾病之用途
TW202402284A (zh) 治療神經病變之方法
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
RU2773943C2 (ru) Соединения и композиции для индуцирования хондрогенеза
CN118382441A (zh) 双环化合物用于治疗疾病的用途